Human EGFR Monoclonal Antibody
Product Sizes
1 mg
£355.00
YR0097-1MG
5 mg
£885.00
YR0097-5MG
20 mg
£2835.00
YR0097-20MG
About this Product
- SKU:
- YR0097
- Additional Names:
- ERBB|ERBB1|ERRP|HER1|mENA|NISBD2|PIG61
- Application:
- Block/Inhibit/Neutralise, Cell-based/Functional Assay, ELISA
- Clonality:
- Monoclonal
- Extra Details:
- Nimotuzumab Biosimilar uses the same protein sequences as the therapeutic antibody nimotuzumab.Like cetuximab, nimotuzumab is a humanized monoclonal antibody that binds to the epidermal growth factor receptor (EGFR), a signalling protein that normally controls cell division. In some cancers, this receptor is altered to cause uncontrolled cell division, a hallmark of cancer. These monoclonal antibodies block EGFR and stop the uncontrolled cell division.It has a humanized human-mouse h-R3 heavy chain and a humanized human-mouse h-R3 K Kappa-chain.Nimotuzumab binds with optimal affinity and high specificity to the extracellular region of EGFR (epidermal growth factor receptor). This results in a blockade of ligand binding and receptor activation. Epidermal growth factor receptor (EGFR) is a key target in the development of cancer therapeutics. EGFR-targeting drugs have been shown to improve response when used with conventional treatments such as radiation therapy and chemotherapy.
- Formulation:
- Purified from cell culture supernatant in an animal-free facility
- Immunogen:
- Human EGFR
- Isotype:
- IgG1, kappa
- Molecular Weight:
- 150 kDa
- Purity:
- >95%
- Shipping Conditions:
- Blue Ice
- Storage Conditions:
- 2-8[o]C Avoid freeze/thaw cycles., -70[o]C Avoid freeze/thaw cycles.
- Supplier:
- ABclonal Technology
- Type:
- Antibody: Biosimilar Antibody
- Manufacturer's Data Sheet:YR0097
